Основы клинической фармакологии противоаритмических средств. Моисеева И.Я - 72 стр.

UptoLike

ВУЗ: 

ПГУ | Пенза

Составители: 

Рубрика: 

74
41. Glassman A. H., Bigger J. T. Jr. Antipsychotic drugs: Proljnged QTc interval,
torsade de pointes, and sudden death/ Am. J. Psychiatry 2001; 158 (11); 1774-
1782.
42. Harrison D.C. Antiarrhythmic Drug Classification: New Scince and Practical
Applications. - Am.J. of Cardiology, 1985. - P.185-187.
43. Jonas M, Reicber-Reiss H, Boyko V et al. Fv j Cardiol 1996;77;1273-7.
44. Kaplan JR, Manusk SB, Adams MR , Clarkson TB. Eur Heart j
1987;8;928-44.
45. Kendall MJ, Lyncb KP, Hjalmarson A, Kjeksbus J. Ann Intern Med 1995;
123; 358-67.
46. Kerr C.R., Rosenbaum M.B., Chiale P.A. Amiodarone. In: F.H. Messerli (ed.)
Cardiovascular drug therapy. 2nd. Philadelphia, 1996, 1247-1267.
47. Locati E. Torsades de pointes. In: Moss A., Stern S. eds. Noninvasive
electrocardiology. Clinical aspects of Holter monitoring. Saunders Co;
University Press, Cambridge, UK; 1997. 59-73
48. Man P.Y.K., Bril A. Effects of class I - V antiarrhythmic drugs in infarcted
tissue. // Clin. and. Ivest. Meд. - 1991. - Vol 14. - N 5. - P. 466 - 475.
49. Meuleman C., Jordain P., Bellorini M. et al. Citalopram and Torsadts de
Pointes. A case report. Arch Mal. Coeur 2001; 94 (9): 1021-1024.
50. Mitcheson J., Chen J., Lin M. et al. A structural basis for druginduced long QT
syndrome. Proc. Natl. Acad. Sci. USA. 2000; 97 (22): 12329-12333.
51. Napolitano C. Schwartz P.J. Brown A.M. et al. Evidence for a cardiac ion
channel mutation underlying drug-induced QT prolongation and life-
threatening arrhythmias. J Cardiovasc Electrophesiol 2000; 11: 691-696.
52. Roden D.M. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc,
Res. 2001; 50(20): 224-231.
53. Romano C., Gemme G., Pongiglione R. Aritmie cardiache rare dell eta
pediatrica 1963; 45: 658-683.
54. Sesti F., Abbott G., Wei J. et al. A common polymorphism associated with
antibiotic-induced cardiac arrhythmia. Ibid. (19): 10613-10618. 
41. Glassman A. H., Bigger J. T. Jr. Antipsychotic drugs: Proljnged QTc interval,
      torsade de pointes, and sudden death/ Am. J. Psychiatry 2001; 158 (11); 1774-
      1782.
42. Harrison D.C. Antiarrhythmic Drug Classification: New Scince and Practical
      Applications. - Am.J. of Cardiology, 1985. - P.185-187.
43. Jonas M, Reicber-Reiss H, Boyko V et al. Fv j Cardiol 1996;77;1273-7.
44. Kaplan JR, Manusk SB, Adams MR , Clarkson TB. Eur Heart j
      1987;8;928-44.
45.    Kendall MJ, Lyncb KP, Hjalmarson A, Kjeksbus J. Ann Intern Med 1995;
      123; 358-67.
46. Kerr C.R., Rosenbaum M.B., Chiale P.A. Amiodarone. In: F.H. Messerli (ed.)
      Cardiovascular drug therapy. 2nd. Philadelphia, 1996, 1247-1267.
47.    Locati E. Torsades de pointes. In: Moss A., Stern S. eds. Noninvasive
      electrocardiology. Clinical aspects of Holter monitoring. Saunders Co;
      University Press, Cambridge, UK; 1997. 59-73
48. Man P.Y.K., Bril A. Effects of class I - V antiarrhythmic drugs in infarcted
      tissue. // Clin. and. Ivest. Meд. - 1991. - Vol 14. - N 5. - P. 466 - 475.
49. Meuleman C., Jordain P., Bellorini M. et al. Citalopram and Torsadts de
      Pointes. A case report. Arch Mal. Coeur 2001; 94 (9): 1021-1024.
50. Mitcheson J., Chen J., Lin M. et al. A structural basis for druginduced long QT
      syndrome. Proc. Natl. Acad. Sci. USA. 2000; 97 (22): 12329-12333.
51. Napolitano C. Schwartz P.J. Brown A.M. et al. Evidence for a cardiac ion
      channel mutation underlying drug-induced QT prolongation and life-
      threatening arrhythmias. J Cardiovasc Electrophesiol 2000; 11: 691-696.
52. Roden D.M. Pharmacogenetics and drug-induced arrhythmias. Cardiovasc,
      Res. 2001; 50(20): 224-231.
53.   Romano C., Gemme G., Pongiglione R. Aritmie cardiache rare dell eta
      pediatrica 1963; 45: 658-683.
54. Sesti F., Abbott G., Wei J. et al. A common polymorphism associated with
      antibiotic-induced cardiac arrhythmia. Ibid. (19): 10613-10618.

                                            74

Страницы